deltatrials
Completed PHASE2 NCT01623713

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions Efficacy Iloperidone Schizophrenia
Interventions Risperidone iloperidone
Updated 6 times since 2017 Last updated: Nov 17, 2013 Started: Jun 30, 2012 Primary completion: Oct 31, 2013 Completion: Nov 30, 2013

Listed as NCT01623713, this PHASE2 trial focuses on Efficacy and Iloperidone and remains completed. Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd., it has been updated 6 times since 2012, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
Data source: Jiangsu Hansoh Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Beijing, China